Hypoxia inducible factor pathway inhibitors as anticancer therapeutics

Future Medicinal Chemistry

Volumn 5, Issue 5, 2013, Pages 553-572

  Burroughs, Sarah K ^a   Kaluz, Stefan ^b   Wang, Danzhu ^a   Wang, Ke ^a   Van Meir, Erwin G ^b   Wang, Binghe ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRA 1,3,5(10),16 TETRAENE 3 CARBOXAMIDE; 2 METHOXYESTRADIOL; ALVESPIMYCIN; ANSAMYCIN DERIVATIVE; ANTINEOPLASTIC AGENT; BORTEZOMIB; CAMPTOTHECIN; ECHINOMYCIN; GELDANAMYCIN; HYPOXIA INDUCIBLE FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IRINOTECAN; MILTEFOSINE; MITOGEN ACTIVATED PROTEIN KINASE; PERIFOSINE; PROTEIN KINASE B; PROTEIN P53; REACTIVE OXYGEN METABOLITE; ROMIDEPSIN; TANESPIMYCIN; TEMSIROLIMUS; TOPOTECAN; UBIQUITIN PROTEIN LIGASE E3;

ACETYLATION; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER GROWTH; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DNA SUPERCOILING; DOWN REGULATION; GENETIC TRANSCRIPTION; HUMAN; IC 50; LUNG SMALL CELL CANCER; METASTASIS; MULTIPLE MYELOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RESPIRATORY CHAIN; REVIEW; SKIN LYMPHOMA; TISSUE SURVIVAL; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UBIQUITINATION; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84876133472     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.17     Document Type: Review

References (226)

1. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26(2), 225-239 (2007).
2. Cairns RA, Kalliomaki T, Hill RP. Acute (cyclic) hypoxia enhances spontaneous metastasis of KHT murine tumors. Cancer Res. 61(24), 8903-8908 (2001).
3. Matsumoto S. Imaging cycling tumor hypoxia. Cancer Res. 70(24), 10019-10023 (2010).
4. Belozerov VE, Van Meir EG. Inhibition of hypoxia-inducible factor-1 signaling. Curr. Opin. Investig. Drugs 7(12), 1067-1076 (2006).
5. Wilson W, Hay M. Targeting hypoxia in cancer therapy. Nat. Rev. Cancer 11(6), 393-410 (2011).
6. Brown JM, Wilson WR. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447 (2004).
7. Graeber TG, Osmanian C, Jacks T et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379(6560), 88-91 (1996).
8. Subarsky P, Hill RP. The hypoxic tumor microenvironment and metastatic progression. Clin. Exp. Metastasis 20(3), 237-250 (2003).
9. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J. Biol. Chem. 270(3), 1230-1237 (1995).
10. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl Acad. Sci. USA 92(12), 5510-5514 (1995).
11. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 22(16), 4082-4090 (2003).
12. Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J. Biol. Chem. 278(33), 30772-30780 (2003).
13. Maxwell PH, Wiesener MS, Chang GW et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733), 271-275 (1999).
14. Ivan M, Kondo K, Yang HF et al. HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292(5516), 464-468 (2001).
15. Jeong JW, Bae MK, Ahn MY et al. Regulation and destabilization of HIF-1a by ARD1- mediated acetylation. Cell 111(5), 709-720 (2002).
16. Wenger RH, Stiehl DP, Camenisch G. Integration of oxygen signaling at the consensus HRE. Sci. STKE 2005(306), re12 (2005).
17. Kimura H, Weisz A, Ogura T et al. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J. Biol. Chem. 276(3), 2292-2298 (2001).
18. Fath DM, Kong X, Liang D et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-a. J. Biol. Chem. 281(19), 13612-13619 (2006).
19. Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM. The oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls expression of distinct genes through the bifunctional transcriptional character of hypoxia-inducible factor-1a. Cancer Res. 66(7), 3688-3698 (2006).
20. Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 30(4), 393-402 (2008).
21. Kaelin Jr WG. ROS: really involved in oxygen sensing. Cell Metab. 1(6), 357-358 (2005).
22. Czibik G. Complex role of the HIF system in cardiovascular biology. J. Mol. Med. 88(11), 1101-1111 (2010).
23. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol. Cell 40(2), 294-309 (2010).
24. Zhao S, Lin Y, Xu W et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1 alpha. Science 324(5924), 261-265 (2009).
25. Dang L, White DW, Gross S et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274), U739-U752 (2009).
26. Koivunen P, Lee S, Duncan CG et al. Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature 483(7390), U485-U144 (2012).
27. Bardos J, Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim. Biophys. Acta 25(2), 107-120 (2005).
28. Déry M-A, Michaud MD, Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. Int. J. Biochem. Cell. Biol. 37(3), 535-540 (2005).
29. Flügel D, Görlach A, Michiels C, Kietzmann T. Glycogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1a and mediates its destabilization in a VHL-independent manner. Mol. Cell. Biochem. 27(9), 3253-3265 (2007).
30. Mottet D, Dumont V, Deccache Y et al. Regulation of hypoxia-inducible factor-1a protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3b pathway in HepG2 cells. J. Biol. Chem. 278(33), 31277-31285 (2003).
31. Flügel D, Görlach A, Kietzmann T. GSK-3b regulates cell growth, migration, and angiogenesis via Fbw7 and USP28-dependent degradation of HIF-1a. Blood 119(5), 1292-1301 (2012).
32. Xu D, Yao Y, Lu L, Costa M, Dai W. Plk3 functions as an essential component of the hypoxia regulatory pathway by direct phosphorylation of HIF-1a. J. Biol. Chem. 285(50), 38944-38950 (2010).
33. Cam H, Easton JB, High A, Houghton PJ. mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1a. Mol. Cell 40(4), 509-520 (2010).
34. Minet E, Arnould T, Michel G et al. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett. 468(1), 53-58 (2000).
35. Gradin K, Takasaki C, Fujii-Kuriyama Y, Sogawa K. The transcriptional activation function of the HIF-like factor requires phosphorylation at a conserved threonine. J. Biol. Chem. 277(26), 23508-23514 (2002).
36. Mottet D, Ruys SPD, Demazy C, Raes M, Michiels C. Role for casein kinase 2 in the regulation of HIF-1 activity. Int J. Cancer 117(5), 764-774 (2005).
37. Richard DE, Berra E, Gothié E, Roux D, Pouysségur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1a (HIF-1a) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274(46), 32631-32637 (1999).
38. Mylonis I, Chachami G, Samiotaki M et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1a. J. Biol. Chem. 281(44), 33095-33106 (2006).
39. Kalousi A, Mylonis I, Politou AS, Chachami G, Paraskeva E, Simos G. Casein kinase 1 regulates human hypoxia-inducible factor HIF- 1. J. Cell Sci. 123(17), 2976-2986 (2010).
40. Van De Sluis B, Mao X, Zhai Y et al. COMMD1 disrupts HIF-1alpha/beta dimerization and inhibits human tumor cell invasion. J. Clin. Invest. 120(6), 2119-2130 (2010).
41. Cho H, Ahn D-R, Park H, Yang EG. Modulation of p300 binding by posttranslational modifications of the C-terminal activation domain of hypoxia-inducible factor-1a. FEBS Lett. 581(8), 1542-1548 (2007).
42. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J. Biol. Chem. 278(22), 19575-19578 (2003).
43. Hu CJ, Wang LY, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF- 2alpha in hypoxic gene regulation. Mol. Cell. Biochem. 23(24), 9361-9374 (2003).
44. Raval RR, Lau KW, Tran MGB et al. Contrasting properties of HIF-1 and HIF-2 in Von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25(13), 5675-5686 (2005).
45. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat. Rev. Cancer 8(12), 967-975 (2008).
46. Gordan JD, Lal P, Dondeti VR et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 14(6), 435-446 (2008).
47. Xu J, Wang B, Xu Y et al. Epigenetic regulation of HIF-1 alpha in renal cancer cells involves HIF-1 alpha/2 alpha binding to a reverse hypoxia-response element. Oncogene 31(8), 1065-1072 (2012).
48. Giatromanolaki A, Koukourakis MI, Sivridis E et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/ molecular profile of tumors and survival. Br. J. Cancer 85(6), 881-890 (2001).
49. Franovic A, Holterman CE, Payette J, Lee S. Human cancers converge at the HIF-2a oncogenic axis. Proc. Natl Acad. Sci. USA 106(50), 21306-21311 (2009).
50. Biswas S, Troy H, Leek R et al. Effects of HIF-1alpha and HIF-2alpha on growth and metabolism of clear-cell renal cancer 786-0 xenografts. J. Oncol. 2010, 757908 (2010).
51. Sowter HM, Raval RR, Moore JW, Ratcliffe PJ, Harris AL. Predominant role of hypoxia-inducible transcription factor (HIF)-1alpha versus HIF-2alpha in regulation of the transcriptional response to hypoxia. Cancer Res. 63(19), 6130-6134 (2003).
52. Aprelikova O, Wood M, Tackett S, Chandramouli GV, Barrett JC. Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res. 66(11), 5641-5647 (2006).
53. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1 alpha. Mol. Cell 38(6), 864-878 (2010).
54. Dioum EM, Chen R, Alexander MS et al. Regulation of hypoxia-inducible factor 2 alpha signaling by the stress-responsive deacetylase sirtuin 1. Science 324(5932), 1289-1293 (2009).
55. Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2 alpha promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell 11(4), 335-347 (2007).
56. Moeller BJ, Dreher MR, Rabbani ZN et al. Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell 8(2), 99-110 (2005).
57. An WG, Kanekal M, Simon MC, Maltepe E, Blagosklonny MV, Neckers LM. Stabilization of wild-type p53 by hypoxia-inducible factor 1 alpha. Nature 392(6674), 405-408 (1998).
58. Bertout JA, Majmundar AJ, Gordan JD et al. HIF2 alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc. Natl Acad. Sci. USA 106(34), 14391-14396 (2009).
59. Hadjipanayis CG, Van Meir EG. Tumor initiating cells in malignant gliomas: biology and implications for therapy. J. Mol. Med. 87(4), 363-374 (2009).
60. Heddleston JM, Li Z, Lathia JD, Bao S, Hjelmeland AB, Rich JN. Hypoxia inducible factors in cancer stem cells. Br. J. Cancer 102(5), 789-795 (2010).
61. Soeda A, Park M, Lee D et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1 alpha. Oncogene 28(45), 3949-3959 (2009).
62. Li Z, Bao S, Wu Q et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6), 501-513 (2009).
63. Pietras A, Hansford LM, Johnsson AS et al. HIF-2 alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc. Natl Acad. Sci. USA 106(39), 16805-16810 (2009).
64. Gustafsson MV, Zheng XW, Pereira T et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 9(5), 617-628 (2005).
65. Covello KL, Kehler J, Yu HW et al. HIF-2 alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20(5), 557-570 (2006).
66. Moreno-Manzano V, Rodriguez-Jimenez FJ, Acena-Bonilla JL et al. FM19G11, a new hypoxia-inducible factor (HIF) modulator, affects stem cell differentiation status. J. Biol Chem. 285(2), 1333-1342 (2010).
67. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev. 17(1), 126-140 (2003).
68. Takahashi K, Tanabe K, Ohnuki M et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5), 861-872 (2007).
69. Ortiz-Barahona A, Villar D, Pescador N, Amigo J, del Peso L. Genome-wide identification of hypoxia-inducible factor binding sites and target genes by a probabilistic model integrating transcription-profiling data and in silico binding site prediction. Nucleic Acids Res. 38(7), 2332-2345 (2010).
70. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies hypoxia inducible factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res. 37(14), 4587-4602 (2009).
71. Tanimoto K, Tsuchihara K, Kanai A et al. Genome-wide identification and annotation of HIF-1a binding sites in two cell lines using massively parallel sequencing. HUGO J. 4(1-4), 35-48 (2010).
72. Schödel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood 117(23), e207-e217 (2011).
73. Mole DR, Blancher C, Copley RR et al. Genome-wide association of hypoxia-inducible factor (HIF)-1a and HIF-2a DNA binding with expression profiling of hypoxia-inducible transcripts. J. Biol. Chem. 284(25), 16767-16775 (2009).
74. Simon MP, Tournaire R, Pouyssegur J. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J. Cell Physiol. 217(3), 809-818 (2008).
75. Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3(4), 347-361 (2003).
76. Lofstedt T, Jogi A, Sigvardsson M et al. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J. Biol. Chem. 279(38), 39223-39231 (2004).
77. Grosfeld A, André J, Hauguel-De Mouzon S, Berra E, Pouysségur J, Guerre-Millo M. Hypoxia-inducible factor 1 transactivates the human leptin gene promoter. J. Biol. Chem. 277(45), 42953-42957 (2002).
78. Melillo G, Musso T, Sica A, Taylor LS, Cox GW, Varesio L. A hypoxia-responsive element mediates a novel pathway of activation of the inducible nitric oxide synthase promoter. J. Exp. Med. 182(6), 1683-1693 (1995).
79. Huang Y, Hickey RP, Yeh JL et al. Cardiac myocyte-specific HIF-1a deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J. 18(10), 1138-1140 (2004).
80. Han Z-B, Ren H, Zhao H et al. Hypoxia-inducible factor (HIF)-1a directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF). Carcinogenesis 29(10), 1853-1861 (2008).
81. Ceradini DJ, Kulkarni AR, Tepper OM et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat. Med. 10(8), 858-864 (2004).
82. Levy AP, Levy NS, Wegner S, Goldberg MA. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270(22), 13333-13340 (1995).
83. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62(12), 3387-3394 (2002).
84. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3́ to the human erythropoietin gene. Proc. Natl Acad. Sci. USA 88(13), 5680-5684 (1991).
85. Miyazaki K, Kawamoto T, Tanimoto K, Nishiyama M, Honda H, Kato Y. Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes. J. Biol. Chem. 277(49), 47014-47021 (2002).
86. Koshiji M, To KKW, Hammer S et al. HIF- 1a induces genetic instability by transcriptionally downregulating MutSa expression. Mol. Cell 17(6), 793-803 (2005).
87. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1: interaction between H-ras and hypoxia. J. Biol. Chem. 276(12), 9519-9525 (2001).
88. Yoon DY, Buchler P, Saarikoski ST, Hines OJ, Reber HA, Hankinson O. Identification of genes differentially induced by hypoxia in pancreatic cancer cells. Biochem. Biophys. Res. Commun. 288(4), 882-886 (2001).
89. Mathupala SP, Rempel A, Pedersen PL. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J. Biol. Chem. 276(46), 43407-43412 (2001).
90. Semenza GL, Jiang B-H, Leung SW et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J. Biol. Chem. 271(51), 32529-32537 (1996).
91. Sonveaux P, Copetti T, De Saedeleer CJ et al. Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF- 1 activation and tumor angiogenesis. PLoS ONE 7(3), e33418 (2012).
92. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 269(38), 23757-23763 (1994).
93. Nishi H, Nakada T, Kyo S, Inoue M, Shay JW, Isaka K. Hypoxia-inducible factor 1 mediates upregulation of telomerase (hTERT). Mol. Cell. Biol. 24(13), 6076-6083 (2004).
94. Synnestvedt K, Furuta GT, Comerford KM et al. Ecto-5́-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110(7), 993-1002 (2002).
95. Huang Y, Hickey RP, Yeh JL et al. Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J. 18(10), 1138-1140 (2004).
96. Krishnamachary B, Berg-Dixon S, Kelly B et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 63(5), 1138-1143 (2003).
97. Ben-Yosef Y, Lahat N, Shapiro S, Bitterman H, Miller A. Regulation of endothelial matrix metalloproteinase-2 by hypoxia/ reoxygenation. Circ. Res. 90(7), 784-791 (2002).
98. Petrella BL, Lohi J, Brinckerhoff CE. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 24(6), 1043-1052 (2005).
99. Staller P, Sulitkova J, Lisztwan J, Moch H, Oakeley EJ, Krek W. Chemokine receptor CXCR4 downregulated by von Hippel- Lindau tumor suppressor pVHL. Nature 425, 307-311 (2003).
100. Erler JT, Bennewith KL, Nicolau M et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440(7088), 1222-1226 (2006).
101. Yang MH, Wu KJ. TWIST activation by hypoxia inducible factor-1 (HIF-1): implications in metastasis and development. Cell Cycle 7(14), 2090-2096 (2008).
102. Wykoff CC, Beasley NJP, Watson PH et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60(24), 7075-7083 (2000).
103. Koshiji M, Kageyama Y, Pete EA, Horikawa I, Barrett JC, Huang LE. HIF-1[alpha] induces cell cycle arrest by functionally counteracting Myc. EMBO J. 23(9), 1949-1956 (2004).
104. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1a and insulin-like growth factor 2. Cancer Res. 59(16), 3915-3918 (1999).
105. Krishnamurthy P, Ross DD, Nakanishi T et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J. Biol. Chem. 279(23), 24218-24225 (2004).
106. Beyer S, Kristensen MM, Jensen KS, Johansen JV, Staller P. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J. Biol. Chem. 283(52), 36542-36552 (2008).
107. Mathieu J, Zhang Z, Zhou W et al. HIF induces human embryonic stem cell markers in cancer cells. Cancer Res. 71(13), 4640-4652 (2011).
108. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634 (2009).
109. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. 23(5), 1011-1027 (2005).
110. Coultas L, Chawengsaksophak K, Rossant J. Endothelial cells and VEGF in vascular development. Nature 438(7070), 937-945 (2005).
111. Liao D, Johnson R. Hypoxia. A key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 26(2), 281-290 (2007).
112. Jensen R, Ragel B, Whang K, Gillespie D. Inhibition of hypoxia inducible factor-1a (HIF-1a) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J. Neurooncol. 78(3), 233-247 (2006).
113. Kim J-W, Gao P, Dang C. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev. 26(2), 291-298 (2007).
114. Balaban RS, Nemoto S, Finkel T. Mitochondria, oxidants, and aging. Cell 120(4), 483-495 (2005).
115. Chiche J, Brahimi-Horn MC, Pouyssegur J. Tumor hypoxia induces a metabolic shift causing acidosis: a common feature in cancer. J. Cell. Mol. Med. 14(4), 771-794 (2010).
116. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumor hypoxia, survival pathway and therapy target. Cell Cycle 3(3), 159-162 (2004).
117. Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5(5), 429-441 (2004).
118. Moeller B, Richardson R, Dewhirst M. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev. 26(2), 241-248 (2007).
119. Chandel NS, Mcclintock DS, Feliciano CE et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia- inducible factor-1a during hypoxia. J. Biol. Chem. 275(33), 25130-25138 (2000).
120. Jung SN, Yang WK, Kim J et al. Reactive oxygen species stabilize hypoxia-inducible factor-1 alpha protein and stimulate transcriptional activity via AMP-activated protein kinase in DU145 human prostate cancer cells. Carcinogenesis 29(4), 713-721 (2008).
121. Brown LM, Cowen RL, Debray C et al. Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1. Mol. Pharmacol. 69(2), 411-418 (2006).
122. Yang DI, Chen SD, Yang YT, Ju TC, Xu JM, Hsu CY. Carbamoylating chemoresistance induced by cobalt pretreatment in C6 glioma cells: putative roles of hypoxia-inducible factor-1. Br. J. Pharmacol. 141(6), 988-996 (2004).
123. Liu L, Ning X, Sun L et al. Hypoxia-inducible factor-1a contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci. 99(1), 121-128 (2008).
124. Sasabe E, Zhou X, Li D, Oku N, Yamamoto T, Osaki T. The involvement of hypoxia-inducible factor-1a in the susceptibility to g-rays and chemotherapeutic drugs of oral squamous cell carcinoma cells. Int. J. Cancer 120(2), 268-277 (2007).
125. Rohwer N, Cramer T. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist. Updat. 14(3), 191-201 (2011).
126. Comerford KM, Wallace TJ, Karhausen JR, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62(12), 3387-3394 (2002).
127. Seagroves TN. The complexity of the HIF-1- dependent hypoxic response in breast cancer presents multiple avenues for therapeutic intervention. In: Pharmaceutical Perspectives of Cancer Therapeutics. Springer Science and Business Media, LLC, NY, USA, 540 (2009).
128. Tan Z, Wu Y, Zhang H, Xiao X. CoCl2- induced chemotherapy resistance in SW480 cells and its mechanism. Zhong Nan Da Xue Xue Bao Yi Xue Ban 31(3), 345-349 (2006).
129. Semenza GL. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol. Sci. 33(4), 207-214 (2012).
130. Xia Y, Choi H-K, Lee K. Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur. J. Med. Chem. 49, 24-40 (2012).
131. Kola L, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug. Discov. 3(8), 1474-1776 (2004).
132. Adams DJ. The valley of death in anticancer drug development: a reassessment. Trends Pharmacol. Sci. 33(4), 173-180 (2012).
133. Atkuri KR, Herzenberg LA, Herzenberg LA. Culturing at atmospheric oxygen levels impacts lymphocyte function. Proc. Natl Acad. Sci. USA 102(10), 3756-3759 (2005).
134. Ivanovic Z. Hypoxia or in situ normoxia: the stem cell paradigm. J. Cell. Physiol. 219(2), 271-275 (2009).
135. Gerweck LE, Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 56(6), 1194-1198 (1996).
136. Gerweck LE, Kozin SV, Stocks SJ. The pH partition theory predicts the accumulation and toxicity of doxorubicin in normal and low-pH-adapted cells. Br. J. Cancer 79(5-6), 838-842 (1999).
137. Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic-thirteenth Bruce F. Cain memorial award lecture. Cancer Res. 55(4), 753-760 (1995).
138. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem. 260(27), 14873-14878 (1985).
139. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl Acad. Sci. USA 99(24), 15387-15392 (2002).
140. Rapisarda A, Uranchimeg B, Sordet O, Pommier Y, Shoemaker RH, Melillo G. Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1. Cancer Res. 64(4), 1475-1482 (2004).
141. Baranello L, Bertozzi D, Fogli MV, Pommier Y, Capranico G. DNA topoisomerase I inhibition by camptothecin induces escape of RNA polymerase II from promoter-proximal pause site, antisense transcription and histone acetylation at the human HIF-1a gene locus. Nucleic Acids Res. 38(1), 159-171 (2010).
142. Rothenberg ML. Irinotecan (CPT-11): recent developments and future directions - colorectal cancer and beyond. Oncologist 6(1), 66-80 (2001).
143. Leblanc R, Catley LP, Hideshima T et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 62(17), 4996-5000 (2002).
144. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 61(7), 3071-3076 (2001).
145. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 10(11), 2034-2042 (2011).
146. Shin DH, Chun Y-S, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 111(6), 3131-3136 (2008).
147. Kaluz S, Kaluzova M, Stanbridge EJ. Proteasomal inhibition attenuates transcriptional activity of hypoxia-inducible factor 1 (HIF-1) via specific effect on the HIF-1a C-terminal activation domain. Mol. Cell. Biol. 26(15), 5895-5907 (2006).
148. Befani C, Vlachostergios P, Hatzidaki E et al. Bortezomib represses HIF-1a protein expression and nuclear accumulation by inhibiting both PI3K/Akt/TOR and MAPK pathways in prostate cancer cells. J. Mol. Med. 90(1), 45-54 (2012).
149. Bross PF, Kane R, Farrell AT et al. Approval summary for Bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. 10(12), 3954-3964 (2004).
150. Ueda H, Nakajima H, Hori Y et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity. J. Antibiot. 47(3), 301-310 (1994).
151. Nakajima H, Kim YB, Terano H, Yoshida M, Horinouchi S. FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. 241(1), 126-133 (1998).
152. Shigematsu N, Ueda H, Takase S, Tanaka H, Yamamoto K, Tada T. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination. J. Antibiot. 47(3), 311-314 (1994).
153. Ueda H, Manda T, Matsumoto S et al. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. III. Antitumor activities on experimental tumors in mice. J. Antibiot. 47(3), 315-323 (1994).
154. Fath DM, Kong X, Liang D et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-1a. J. Biol. Chem. 281(19), 13612-13619 (2006).
155. Qian DZ, Kachhap SK, Collis SJ et al. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1a. Cancer Res. 66(17), 8814-8821 (2006).
156. Rini BI. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 14(5), 1286-1290 (2008).
157. Thomas GV, Tran C, Mellinghoff IK et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 12(1), 122-127 (2006).
158. Hudson CC, Liu M, Chiang GG et al. Regulation of hypoxia-inducible factor 1a expression and function by the mammalian target of rapamycin. Mol. Cell. Biol. 22(20), 7004-7014 (2002).
159. Zhong H, Chiles K, Feldser D et al. Modulation of hypoxia-inducible factor 1a expression by the epidermal growth factor/ phosphatidylinositol 3-kinase/PTEN/AKT/ FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60(6), 1541-1545 (2000).
160. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK. Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol. Cancer Ther. 2(11), 1093-1103 (2003).
161. Ghobrial IM, Leleu X, Rubin N et al. Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). J. Clin. Oncol. 26(Suppl. 15), 8546 (2008).
162. Lakhani NJ, Sarkar MA, Venitz J, Figg WD. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 23(2), 165-172 (2003).
163. Mabjeesh NJ, Escuin D, Lavallee TM et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3(4), 363-375 (2003).
164. Carbonaro M, O'Brate A, Giannakakou P. Microtubule disruption targets HIF-1a mRNA to cytoplasmic P-bodies for translational repression. J. Cell Biol. 192(1), 83-99 (2011).
165. Dahut WL, Lakhani NJ, Gulley JL et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol. Ther. 5(1), 22-27 (2006).
166. Harrison MR, Hahn N, Pili R et al. Phase II study of 2-methoxyestradiol (2ME2) NanoCrystal Dispersion (NCD) in patients with taxane-refractory, metastatic hormone-refractory prostate cancer (HRPC). J. Clin. Oncol. 26(Suppl. 15), 5173 (2008).
167. Bruce J, Eickhoff J, Pili R et al. A Phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate. Invest. New Drugs 30(2), 794-802 (2012).
168. Formica JV, Waring MJ. Effect of phosphate and amino acids on echinomycin biosynthesis by Streptomyces echinatus. Antimicrob. Agents Chemother. 24(5), 735-741 (1983).
169. Van Dyke M, Dervan P. Echinomycin binding sites on DNA. Science 225(4667), 1122-1127 (1984).
170. Nickols NG, Jacobs CS, Farkas ME et al. Modulating hypoxia-inducible transcription by disrupting the HIF-1-DNA interface. ACS Chem. Biol. 2(8), 561-571 (2007).
171. Kong D, Park EJ, Stephen AG et al. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res. 65(19), 9047-9055 (2005).
172. Onnis B, Rapisarda A, Melillo G. Development of HIF-1 inhibitors for cancer therapy. J. Cell. Mol. Med. 13(9a), 2780-2786 (2009).
173. Deboer C, Meulman PA, Wnuk RJ, Peterson DH. Geldanamycin, a new antibiotic. J. Antibiot. 23(9), 442-447 (1970).
174. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc. Natl Acad. Sci. USA 97(20), 10832-10837 (2000).
175. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc. Natl Acad. Sci. USA 91(18), 8324-8328 (1994).
176. Dehner A, Furrer J, Richter K, Schuster I, Buchner J, Kessler H. NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol. ChemBioChem 4(9), 870-877 (2003).
177. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 11(7), 515-528 (2010).
178. Bagatell R, Whitesell L. Altered Hsp90 function in cancer: a unique therapeutic opportunity. Mol. Cancer Ther. 3(8), 1021-1030 (2004).
179. Minet E, Mottet D, Michel G et al. Hypoxia-induced activation of HIF-1: role of HIF- 1alpha-Hsp90 interaction. FEBS Lett. 460(2), 251-256 (1999).
180. Mabjeesh NJ, Post DE, Willard MT, Kaur B et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res. 62(9), 2478-2482 (2002).
181. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother. Pharmacol. 36(4), 305-315 (1995).
182. Neckers LM. Chaperoning oncogenes: Hsp90 as a target of geldanamycin. Handb. Exp. Pharmacol. 172, 259-277 (2006).
183. Richardson PG, Chanan-Khan AA, Alsina M et al. Tanespimycin monotherapy in relapsed multiple myeloma: results of a Phase I dose-escalation study. Br. J. Haematol. 150(4), 438-445 (2010).
184. Solit DB, Osman I, Polsky D et al. Phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with metastatic melanoma. Clin. Cancer Res. 14(24), 8302-8307 (2008).
185. Ronnen EA, Kondagunta GV, Ishill N et al. A Phase II trial of 17-(allylamino)-17- demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest. New Drugs 24(6), 543-546 (2006).
186. Heath EI, Hillman DW, Vaishampayan U et al. A Phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin. Cancer Res. 14(23), 7940-7946 (2008).
187. Pacey S, Wilson RH, Walton M et al. A Phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin. Cancer Res. 17(6), 1561-1570 (2011).
188. Kaufmann SH, Karp JE, Litzow MR et al. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 96(11), 1619-1626 (2011).
189. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol. Oncol. 6(2), 155-176 (2012).
190. Valkov E, Sharpe T, Marsh M, Greive S, Hyvönen M. Targeting protein-protein interactions and fragment-based drug discovery. In: Fragment-Based Drug Discovery and X-Ray Crystallography. Davies TG, Hyvönen M (Eds). Springer Berlin/ Heidelberg, Germany, 145-179 (2012).
191. Verdine GL, Hilinski GJ. All-hydrocarbon stapled peptides as synthetic cell-accessible mini-proteins. Drug Discov. Today Technol. 9(1), e41-e47 (2012).
192. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin. Cancer Res. 14(17), 5318-5324 (2008).
193. Higueruelo AP, Schreyer A, Bickerton GRJ, Pitt WR, Groom CR, Blundell TL. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem. Biol. Drug Des. 74(5), 457-467 (2009).
194. Fry DC. Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr. Protein Pept. Sci. 9(3), 240-247 (2008).
195. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46(1-3), 3-26 (2001).
196. M. Monti S, T. Supuran C, De Simone G. Carbonic anhydrase IX as a target for designing novel anticancer drugs. Curr. Med. Chem. 19(6), 821-830 (2012).
197. Mylonis I, Lakka A, Tsakalof A, Simos G. The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions. Biochem. Biophys. Res. Commun. 398(1), 74-78 (2010).
198. Nagle D-G, Zhou Y-D. Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr. Drug Targets 7(3), 355-369 (2006).
199. Lakka A, Mylonis I, Bonanou S, Simos G, Tsakalof A. Isolation of hypoxia-inducible factor 1 (HIF-1) inhibitors from frankincense using a molecularly imprinted polymer. Invest. New Drugs 29(5), 1081-1089 (2011).
200. Lee K, Zhang H, Qian DZ, Rey S, Liu JO, Semenza GL. Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc. Natl Acad. Sci. USA 106(42), 17910-17915 (2009).
201. Scheuermann TH, Tomchick DR, Machius M, Guo Y, Bruick RK, Gardner KH. Artificial ligand binding within the HIF2a PAS-B domain of the HIF2 transcription factor. Proc. Natl Acad. Sci. USA 106(2), 450-455 (2009).
202. Kung AL, Zabludoff SD, France DS et al. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6(1), 33-43 (2004).
203. Cook KM, Hilton ST, Mecinović J, Motherwell WB, Figg WD, Schofield CJ. Epidithiodiketopiperazines block the interaction between hypoxia-inducible factor- 1a (HIF-1a) and p300 by a zinc ejection mechanism. J. Biol. Chem. 284(39), 26831-26838 (2009).
204. Henchey LK, Kushal S, Dubey R, Chapman RN, Olenyuk BZ, Arora PS. Inhibition of hypoxia inducible factor 1-transcription coactivator interaction by a hydrogen bond surrogate a-helix. J. Am. Chem. Soc. 132(3), 941-943 (2009).
205. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. Oncogene 22(14), 2065-2072 (2003).
206. Post DE, Devi NS, Li ZC et al. Cancer therapy with a replicating oncolytic adenovirus targeting the hypoxic microenvironment of tumors. Clin. Cancer Res. 10(24), 8603-8612 (2004).
207. Post DE, Sandberg EM, Kyle MM et al. Targeted cancer gene therapy using a hypoxia inducible factor-dependent oncolytic adenovirus armed with interleukin-4. Cancer Res. 67(14), 6872-6881 (2007).
208. Tan C, de Noronha RG, Roecker AJ et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 65(2), 605-612 (2005).
209. Narita T, Yin S, Gelin CF et al. Identification of a Novel Small Molecule HIF-1 alpha Translation Inhibitor. Clin. Cancer Res. 15(19), 6128-6136 (2009).
210. Tan C, de Noronha RG, Devi NS et al. Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors. Bioorg. Med. Chem. Lett. 21(18), 5528-5532 (2011).
211. Mooring SR, Jin H, Devi NS et al. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway. J. Med. Chem. 54(24), 8471-8489 (2011).
212. Mun J, Jabbar AA, Devi NS, Liu Y, Van Meir EG, Goodman MM. Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl) methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent. Bioorg. Med. Chem. 20(14), 4590-4597 (2012).
213. Mun J, Jabbar AA, Devi NS et al. Design and in vitro activities of N-alkyl-N-[(8-R-2,2- dimethyl-2H-chromen-6-yl)methyl] heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents. J. Med. Chem. 55(15), 6738-6750 (2012).
214. Shi Q, Yin S, Kaluz S et al. Binding model for the interaction of anticancer arylsulfonamides with the p300 transcription cofactor. ACS Med. Chem. Lett. 3(8), 620-625 (2012).
215. Yin S, Kaluz S, Devi NS et al. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1 alpha interaction with cofactors p300/CBP. Clin. Cancer Res. 18(24), 6623-6633 (2012).
216. Wang W, Ao L, Rayburn ER et al. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology. PLoS ONE 7(9), e44883 (2012).
217. American Cancer Society. Cancer facts and figures 2011. www.cancer.org/Research/ CancerFactsFigures/CancerFactsFigures/ cancer-facts-figures-2011 (Accessed 11 April 2012
218. World Cancer Research Fund International. General world cancer statistics: GLOBOCAN 2008 database. www.wcrf.org/cancer-statistics/world- cancer-statistics.php (Accessed 1 April 2012
219. US FDA approves topotecan hydrochloride (hycamtin) in combination with cisplatin for the treatment of Stage IVB recurrent or persistent carcinoma of the cervix. www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/ CDER/ucm095638.htm (Accessed 30 April 2012
220. GlaxoSmith Kline receives approval for hycamtin (topotecan) capsules for the treatment of relapsed small cell lung cancer. www.drugs.com/newdrugs/gsk- receives-approval-hycamtin-topotecan-capsules-relapsed-small-cell-lung-cancer- 671.html (Accessed 4 May 2012
221. National Cancer Institute. Romidepsin. www.cancer.gov/cancertopics/ druginfo/ romidepsin (Accessed 1 June 2011
222. US FDA approves new drug for advanced kidney cancer. www.fda.gov/ NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108924.htm (Accessed 4 May 2012
223. Genetic Engineering & Biotechnology News. Aeterna Zentaris regains North American rights to Akt inhibitor from Keryx. www.genengnews.com/gen-news- highlights/ aeterna-zentaris-regains-north-american-rights-to-akt-inhibitor- from-keryx/81246731/ (Accessed 11 May 2012
224. Patent Database Search Results: ISD 1/1/2000->12/31/2012 AND HIF AND cancer AND inhibitor in US Patent Collection. http://patft.uspto.gov/netacgi/ nph-Parser?Sec t1=PTO2&Sect2=HITOFF&u=%2Fnetaht ml%2FPTO%2Fsearch-adv. htm&r=0&f=S &l=50&d=PTXT&RS=%28%28%28ISD% 2F20120101-%3E20121231+AND+HIF%29 +AND+Cancer%29+AND+inhibitor%29& Refine=Refine+Search&Refine=Refine+Sear ch&Query=ISD%2F1%2F1%2F2000-%3E1 2%2F31%2F2012+AND+HIF+AND+Canc er+AND+inhibitor (Accessed 26 February 2013
225. Web of Knowledge - All Database Results: Topic=(HIF AND CANCER AND INHIBITOR) Timespan=2000-2012. http://apps.webofknowledge.com/summary. do?SID=1F83DLk7akON2aaKN9E&produc t=UA&qid=18&search- mode=GeneralSearch (Accessed 26 February 2013
226. Search of: HIF and cancer - List Results - ClinicalTrials.gov. www.clinicaltrials.gov/ct2/results?term=hif+a nd+cancer+&Search=Search (Accessed 26 February 2013